裕太微(688515.SH):已規模量產的車載以太網物理層芯片已批量應用於多款新能源汽車
格隆匯7月22日丨裕太微(688515.SH)近日在接待機構投資者調研時表示,據“中汽協會數據”微信號消息,據中國汽車工業協會分析,2024年6月,新能源汽車產銷繼續保持較快增長,同比均超過兩位數。2024年6月,新能源汽車產銷分別完成100.3萬輛和104.9萬輛,同比分別增長28.1%和30.1%。2024年1-6月,新能源汽車產銷分別完成492.9萬輛和494.4萬輛,同比分別增長30.1%和32%。公司已規模量產的車載以太網物理層芯片已批量應用於多款新能源汽車。後續,隨着汽車架構中端到端應用的不斷深化,將有更多車型使用公司車載產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.